Centene Q3 revenue tops estimates on Medicare growth

By Reuters News


Overview

  • U.S. managed care firm's Q3 revenue rose, beating analyst expectations

  • Adjusted EPS for Q3 beat consensus

  • Company raised 2026 adjusted EPS guidance and improved HBR outlook


Outlook

  • Centene raises 2026 GAAP diluted EPS guidance to greater than $3.46

  • Centene lifts 2026 adjusted diluted EPS guidance to greater than $5.20

  • Company lowers 2026 HBR guidance range to 90.4%-91.1%


Result Drivers

  • MEDICARE GROWTH - Co said Q3 revenue increase was driven by premium yield and membership growth in Medicare Prescription Drug Plan (PDP) business

  • MARKETPLACE PRICING - Co said improved pricing and risk transfer in Marketplace segment lowered health benefits ratio

  • COST MANAGEMENT - Co said decrease in adjusted SG&A expense ratio was driven by strong cost management and reduced Marketplace membership


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$50.65 bln

$47.11 bln (15 Analysts)

Q3 Adjusted EPS

Beat

$0.58

$0.10 (19 Analysts)

Q3 Loss Per Share

$0.14


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 13 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the managed healthcare peer group is "buy"

  • Wall Street's median 12-month price target for Centene Corp is $71.00, about 4.4% above its October 26 closing price of $68.03

  • The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 16 three months ago


Reuters Recommended Reads

  • Oct 26 - Hartford Insurance Q3 core EPS beats estimates; dividend raised

  • Oct 26 - Cincinnati Financial Q3 adj EPS beats estimates

  • Oct 26 - Panama's Bladex Q3 net profit rises on higher business volumes


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.